Literature DB >> 32258719

Studies towards the synthesis of dicarboxylic acid metabolite of mitoxantrone: PS177.

Ivanna Hrynchak1, Emília Sousa1,2, Maria de Lourdes Bastos1,2,3, Madalena Pinto1,2, Vera Marisa Costa3.   

Abstract

Entities:  

Year:  2017        PMID： 32258719      PMCID： PMC6806919          DOI： 10.1016/j.pbj.2017.07.107

Source DB:  PubMed          Journal:  Porto Biomed J        ISSN： 2444-8664


× No keyword cloud information.
  5 in total

Review 1.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

2.  Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.

Authors:  A Reis-Mendes; A S Gomes; R A Carvalho; F Carvalho; F Remião; M Pinto; M L Bastos; E Sousa; V M Costa
Journal:  Arch Toxicol       Date:  2016-09-14       Impact factor: 5.153

Review 3.  Mitoxantrone: a new anticancer drug with significant clinical activity.

Authors:  T D Shenkenberg; D D Von Hoff
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

4.  Identification of human urinary mitoxantrone metabolites.

Authors:  F S Chiccarelli; J A Morrison; D B Cosulich; N A Perkinson; D N Ridge; F W Sum; K C Murdock; D L Woodward; E T Arnold
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

5.  The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.

Authors:  Ana Filipa Reis-Mendes; Emília Sousa; Maria de Lourdes Bastos; Vera Marisa Costa
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.